tbuckley/cabot-search huggingface dataset:
Satisfaction with physician–patient discussions on fertility and sexual health among young women with cancer.
Authors: M. M. Scanlon, A. H. Blaes, M. A. Geller, N. S. Majhail, T. C. Haddad
Journal: Journal of Clinical Oncology (2010)

9048 Background: Young women with a new diagnosis of cancer grapple with several important issues when deciding on treatment options. For pre-menopausal women, the risks of infertility and premature menopause due to cancer therapy are frequently overlooked in physician-patient discussions during treatment planning. Methods: We designed a 24 item questionnaire to assess the frequency and quality of discussions of cancer therapy impact on fertility, menopausal status and general sexual health and distributed it in 4 oncology clinics: breast cancer, gynecologic oncology, general oncology, and bone marrow transplant (BMT). Participants had to be pre-menopausal at diagnosis and within 24 months of completing cancer treatment. Results: Completed questionnaires were obtained from 114 women of 126 screened, and 10 were excluded from analysis due to ineligibility. Overall, 66% of women were satisfied with the quality and length of reproductive health discussions, with lowest satisfaction levels in BMT (53%) and highest in gynecologic clinics (85%). Of those women with a male oncologist, 23% reported dissatisfaction with the quality of discussions as compared with 13% of those with a female oncologist. A relatively large proportion of women desired to preserve fertility during treatment, including 46% >35 years, 18% 35-39 years and 15% ≥40 years of age. Risk of infertility influenced choice of therapy in 14% of all women. Overall, 33% of women wanted to discuss and 70% reported physician discussion of impact of therapy on fertility. Of the women who were not interested in becoming pregnant, 8% ranked fertility issues as important to discuss. Also, 56% wanted to discuss and 35% reported physician discussion of impact of therapy on sexual health. More than half of all women sought out additional resources on these topics. Conclusions: Most oncologists address cancer therapy impact on fertility during treatment planning discussions. However, there is a relative lack of discussion between physicians and women about its impact on general sexual health. Satisfaction regarding discussions on these topics may vary depending on oncologic specialty clinic, a woman's age, and the gender of her oncologist. No significant financial relationships to disclose.
Artificial Basilar Membranes: A Triboelectric‐Based Artificial Basilar Membrane to Mimic Cochlear Tonotopy (Adv. Healthcare Mater. 19/2016)
Authors: Jongmoon Jang, JangWoo Lee, Jeong Hun Jang, Hongsoo Choi
Journal: Advanced Healthcare Materials (2016)

Hongsoo Choi and co-workers use the triboelectric effect to fabricate novel triboelectric-based artificial basilar membranes (TEABM) for acoustic-to-electric energy conversion on page 2481. The TEABM is applied to generate auditory evoked potential to realize cochlear tonotopy using an animal model. The electrically evoked auditory brainstem response signals from deafened guinea pigs were measured by converting an acoustic stimulus to electricity.
Meningococcal serogroup B-specific responses after vaccination with bivalent rLP2086: 4 year follow-up of a randomised, single-blind, placebo-controlled, phase 2 trial
Authors: Helen S Marshall, Peter C Richmond, Johannes Beeslaar, Qin Jiang, Kathrin U Jansen, Maria Garcés-Sánchez, Federico Martinón-Torres, Leszek Szenborn, Jacek Wysocki, Joseph Eiden, Shannon L Harris, Thomas R Jones, Su-San Lee, John L Perez
Journal: The Lancet Infectious Diseases (2016)
A phase I study of cediranib plus whole-brain radiation therapy in patients with brain metastases from non-small cell lung cancer.
Authors: A. F. Eichler, H. A. Shih, L. V. Sequist, P. Y. Wen, R. K. Jain, A. G. Sorensen, T. Batchelor
Journal: Journal of Clinical Oncology (2010)

TPS177 Background: Brain metastases (BM) are common in patients with non-small cell lung cancer (NSCLC), and whole-brain radiation therapy (WBRT) is associated with only modest benefit in many patients and a median survival of 4.5 months. Cediranib is an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor with potent anti-edema effects in glioblastoma patients (Batchelor 2007) and clinical activity in NSCLC when given in combination with chemotherapy (Goss 2010). Preclinical data also suggests that angiogenesis inhibition may potentiate the antitumor effects of radiation (Lee 2000, Winkler 2004, Cao 2006, Dings 2007, Williams 2008). The goal of this phase I study is to establish safety of cediranib when given in combination with WBRT in patients with BM from NSCLC. Methods: Eligibility: newly diagnosed BM; histologically confirmed NSCLC; ≥1 cm measurable disease in brain; no prior therapy for BM; ≥ 12 weeks elapsed since diagnosis of NSCLC; stable primary tumor; no oral anticoagulants; no history of brain hemorrhage or significant hemoptysis; able to undergo magnetic resonance imaging (MRI). Study design: standard 3+3 dose escalation starting at 20 mg oral daily, planned sample size 9-18. Treatment: cediranib 20-45 mg oral daily starting 2 days before WBRT (35Gy in 14 fractions) and continuing until progression at any site. Restaging evaluations of both brain and systemic disease will occur 1 month after completion of WBRT and every 2 months thereafter. Primary endpoint: safety and tolerability. Secondary endpoints: objective response rate in brain, time to neurological progression, overall survival, cause of death. Correlative studies: serial non-invasive vascular MRI (dynamic contrast enhanced MRI, arterial spin labeling and perfusion weighted imaging) will be performed on days -1, 1, 21, 49 to explore changes in tumor perfusion, permeability and blood flow and to define presence or absence of vascular normalization. Current enrollment: Dose level 1 is open for enrollment. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration AstraZeneca, Dyax, Genentech, Millennium, Novartis, Regeneron, SynDevRx SynDevRx Pfizer AstraZeneca, Genentech, Novartis, Takeda
PKC412 Effectively Inhibits Constitutively Activated FGFR3 Mutants in Murine Leukemia Models and t(4;14) Myeloma Cell Lines.
Authors: Jing Chen, Benjamin H. Lee, Ifor R. Williams, Jeffery L. Kutok, Nicole Duclos, Sarah Cohen, Jennifer Adelsperger, Rachel Okabe, Allison Coburn, Sandra Moore, Brian J.P. Huntly, Constantine S. Mitsiades, Kenneth C. Anderson, James D. Griffin, Doriano Fabbro, D. Gary Gilliland
Journal: Blood (2004)
TCT-756 CHADS2 and CHA2DS2-VASc Scores in Atrial Fibrillation: Which Patients Actually Have Strokes?
Authors: Rahul Malik, Abdalla Hassan, Ibett Colina, Raina Gupta, Minna B. Masor, Dana Villines, Lloyd W. Klein
Journal: Journal of the American College of Cardiology (2015)
TCT-282 The combination of high Syntax Score and moderate to severe Coronary Artery Calcification is a strong predictor of thrombotic events after an Acute Coronary Syndrome
Authors: Roberto Martin-Reyes, Juan Antonio Franco Pelaez, Rocio Carda Barrio, Ana M. Pello Lazaro, Alvaro Acena Navarro, Oscar Gonzalez Lorenzo, Jose Luis Martin Ventura, Luis M. Blanco Colio, Jesus Egido de los Rios, Jose Tunon Fernandez
Journal: Journal of the American College of Cardiology (2015)
Effective Treatment of Biphenotypic Acute Leukemia in Children with Chemotherapy Alone.
Authors: Amal S. Al-Seraihy, Mouhab Ayas, Tarek Owaidah, Hassan El-Solh, Mohammed Al-Mahr, Abdulrahman Al-Musa, Mahasen S. Al-Saleh, Ali Al-Ahmari, Asim F. Belgaumi
Journal: Blood (2006)
Patients with Chronic Myeloid Leukemia In Chronic Phase Carrying More Than One BCR-ABL Kinase Domain Mutation Exhibit Poorer Response Rates and Outcomes to Second-Line Dasatinib Compared to Those with No or Only One BCR-ABL Mutation
Authors: Alfonso Quintás-Cardama, Hagop Kantarjian, Neil P. Shah, Charles A. Schiffer, Philipp le Coutre, Giuseppe Saglio, Francois Guilhot, Andreas Hochhaus, Martin C. Müller, Erkut Bahceci, Alexandre Lambert, Jorge E. Cortes
Journal: Blood (2010)
WBC More Than 300 *109/L Confers an Adverse Outcome in Pediatric Acute Lymphoblastic Leukemia Patients Treated By Protocol(CCLG-2008 )
Authors: Shaoyan Hu, Xiao-yan Yang, Hai-long He, Jun LU, Yi WANG, Wenli Zhao, Peifang Xiao, Yi-huan Chai
Journal: Blood (2014)
AABB Red Blood Cell Transfusion Guidelines
Authors: Mark H. Yazer, Darrell J. Triulzi
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
TCT-616 Utility And Safety Of Temporary Pacing Using Active-fixation Leads And Externalized Re-Usable Permanent Pacemakers In Transcatheter Aortic Valve Implantation
Authors: Stefan Schwarz, Jürgen Kammler, Alexander Kypta, Karim Saleh, Simon Hönig, Thomas Lambert, Michael Grund, Hermann Blessberger, Alexander Nahler, Clemens Steinwender
Journal: Journal of the American College of Cardiology (2015)
TCT-734 Heart Failure Functional Classification Following Transcatheter versus Surgical Aortic Valve Replacement: a Meta-Analysis of Three Randomized Controlled Trials
Authors: Rhanderson N. Cardoso, Mohammad M. Ansari, Rodrigo Mendirichaga, Daniel C. Garcia, Derek Brinster, Nirav C. Patel, S Jacob Scheinerman, Giuseppe Martucci, Nicolo Piazza
Journal: Journal of the American College of Cardiology (2015)
GW27-e0709 Effects of pacemaker implantation on sudden cardiac death rate and quality of life in atrial fibrillation patients with ventricular pauses
Authors: Li Yaodong, Hong Yi-fan, Ma Jian-hua, Cao Gui-qiu, Zhou Xian-hui, Zhang Jiang-hua, Xing Qiang, Tang Bao-peng
Journal: Journal of the American College of Cardiology (2016)
A Phase I Study of Carfilzomib and Pegylated Liposomal Doxorubicin for Relapsed or Refractory Multiple Myeloma
Authors: Jesse Keller, Mark A Fiala, Jeevan Sekhar, Connie Ceriotti, Melissa Allen, Camille N. Abboud, Keith E. Stockerl-Goldstein, Tanya M Wildes, Michael H. Tomasson, Ravi Vij
Journal: Blood (2014)
Treosulfan Based Conditioning Prior To Allogeneic Stem Cell Transplantation (HSCT) For Acute Myelogenous Leukemia (AML): A Retrospective Analysis From The ALWP Of The EBMT
Authors: Arnon Nagler, Myriam Labopin, Avichai Shimoni, Dietrich Beelen, Slawomira Kyrcz-Krzemien, Kerstin Schufer-Eckart, Liisa Volin, Michael Hallek, Laimonas Griskevicius, Igor-Wolfgang Blau, Jochen Casper, Fabio Ciceri, Mohamad Mohty
Journal: Blood (2013)
Intensified loading schedule of trastuzumab with concurrent taxane: Pilot study of cardiotoxicity and safety monitoring.
Authors: Lenka Zvirinska
Journal: Journal of Clinical Oncology (2012)

e13112 Background: Recent update of NCCGT trial (Perez et al. J Clin Oncol. 2011;29:4491-4497) has shown only minor trend toward improvement in DFS with concurrent administration of chemotherapy with Transtuzumab. However data on pharmacokinetics of trastuzumab (Leyland-Jones et al. J Clin Oncol. 2010;28:960-966) suggest that more intense loading schedule could achieve effective levels earlier which might be vital for optimal effect. Methods: Therefore we have analysed data of patient cohort treated in single institution (UHCW), in the first instance monitoring difference in cardiotoxicity in patients treated by standard concurrent trastuzumab + taxane regime (8mg/kg followed by 3 weekly 6mg/kg) compared to patients treated with slightly intensified trastuzumab regime (8 mg/kg followed by 6 mg/kg a week later and continue starting with standard 3 weekly 6 mg/kg dose). Results: Altogether 34 patients have been identified starting treatment with trastuzumab in UHCW between October 2008 and October 2010. Median follow up was 12 months (8- 48). 20 were treated by standard concurrent regime, 14 by intensified. 30 patients received 300 – 400mg/m 2 of epirubicin prior to trastuzumab. EF was monitored by MUGA every 3 months as per NICE recommendations at the time.
PDE4B Modulates Glucocorticoid Sensitivity in Childhood Acute Lymphoblastic Leukemia
Authors: Jun J. Yang, Shuyu E, Shuhong Shen, Deepa Bhojwani, Huining Kang, Yani Ma, Jing Chen, JingYan Tang, Nita L. Seibel, Heng Xu, Jin Cheng, Laura B. Ramsey, Kristine Crews, W. Paul Bowman, Michael J. Borowitz, William L. Carroll, Cheryl L. Willman, Sima Jeha, Ching-Hon Pui, Stephen P. Hunger, Mary V. Relling, William E. Evans
Journal: Blood (2012)
TCT-399 Long-Term Impact Of Iatrogenic Dissection Of A Left Main Coronary Artery During Percutaneous Coronary Intervention
Authors: Smita I. Negi, Romain Didier, Won Yu Kang, Sarkis Kiramijyan, Edward Koifman, Jiaxiang Gai, Rebecca Torguson, Itsik Ben Dor, William O. Suddath, Augusto Pichard, Lowell F. Satler, Ron Waksman
Journal: Journal of the American College of Cardiology (2015)
Acquired Stem Cell Properties In Therapy-Induced Senescence Of Lymphomas and Acute Leukemias In Vitro and In Vivo
Authors: J. Henry M. Däbritz, Maja Milanovic, Zhen Zhao, Jan R. Dörr, Yong Yu, Dido Lenze, Bernd Dörken, Michael Hummel, Christoph Dieterich, Scott W. Lowe, Clemens A. Schmitt
Journal: Blood (2013)
Efficacy of Dasatinib in Patients with Philadelphia-Chromosome-Positive Acute Lymphoblastic Leukemia Who Are Resistant or Intolerant to Imatinib: 2-Year Follow-Up Data from START-L (CA180-015).
Authors: Kimmo Porkka, Bengt Simonsson, Herve Dombret, Giovanni Martinelli, Oliver G. Ottmann, Chao Zhu, Jan M.A. Van Tornout, Felix T. Garzon, Richard A. Larson
Journal: Blood (2007)
GW27-e1180 Semi-automatic Assessment of Normal Human Aortic Roots by Three-dimensional Transesophageal Echocardiography: Results from the SMARTER Registry
Authors: Minghui Zhang, Linyuan Wan, Weichun Wu, Kun Liu, Li Zhang, Zhilan Zheng, Hui Li, Yan Sun, Yisheng Shi, Zhenhui Zhu, Bin Lyu, Hao Wang
Journal: Journal of the American College of Cardiology (2016)
Ictal Phase Perfusion SPECT of Nonketotic Hyperglycemia-Induced Parieto-occipital Seizure
Authors: Chia-Ju Liu, Hsin-Hsi Tsai, Kuan-Yin Ko, Ching-Chu Lu, Ruoh-Fang Yen
Journal: Clinical Nuclear Medicine (2016)

A 68-year-old man with diabetes mellitus type 2 presented himself with visual distortion and apraxia. Nonketotic hyperglycemic seizure with both motor and sensory components was suspected. 99mTc-ECD perfusion SPECT demonstrated hyperperfusion at right parieto-occipital lobe during ictal phase. Normalization of hyperperfused area was noted on follow-up perfusion SPECT after intense glucose control. In nonketotic hyperglycemic state, the depletion of GABA in cerebral neurons lowers the seizure threshold. We demonstrated that ictal phase perfusion SPECT contributed to not only diagnosis but also served as a follow-up tool.
Acute Lymphoblastic Leukaemia Has a Poor Outcome in Children with Down Syndrome Due to Infective Death in Remission (Results of UK MRC ALL 97 Trial).
Authors: Josu de la Fuente, Sue Richards, David K. Webb, Ian M. Hann, Christopher D. Mitchell, Ajay J. Vora, Sally E. Kinsey, Osborn B. Eden, Phil Ancliff
Journal: Blood (2005)
Favorable Outcome and Quality of Life in Patients Surviving 5 or More Years After Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies.
Authors: Robert Quan Le, Margaret Bevans, Bipin N. Savani, Sandra Mitchell, Kate Stringaris, Eleftheria K. Koklanaris, A. John Barrett
Journal: Blood (2009)
Primary Tumor Sidedness as Prognostic and Predictive Biomarker in Metastatic Colorectal Cancer
Authors: Kristen K. Ciombor, Richard M. Goldberg
Journal: JAMA Oncology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
TCT-684 Approach and Procedural Management in Patients Undergoing Transcatheter Aortic Valve Implantation: Results From The Written (WoRldwIde TAVI ExperieNce) Survey
Authors: Enrico Cerrato, Luis Nombela-Franco, Helene Eltchaninoff, Henrique B. Ribeiro, Lars Søndergaard, Marco Barbanti, Fabian Nietlispach, Peter De Jaegere, Pierfrancesco Agostoni, Pilar Jimenez-Quevedo, Ramiro Trillo, Claudio Moretti, Olaf Wendler, Gabriel Maluenda, Antonio Fernandez-Ortiz, Corrado Tamburino, Carlos Macaya, Josep Rodes-Cabau
Journal: Journal of the American College of Cardiology (2015)
Efficacy and Safety of Monoclonal Anti-CD20 Antibody Rituximab Combined Cyclophosphamide in Treatment of Refractory and Recurrent Autoimmune Hemolytic Anemia
Authors: Zonghong Shao, Hong Liu, Limin Xing, Yuhong Wu, Wen Qu, Yong Liang, Jing Guan, Guojin Wang, Xiaoming Wang, Jia Song, Lijuan Li, Huaquan Wang
Journal: Blood (2012)
TCT-718 Percutaneous mitral valve repair in functional mitral regurgitation: preliminary results from the of the Swiss nationwide investigator-initiated prospective MitraClip® registry (MitraSwiss)
Authors: Daniel Suerder, Roberto Corti, Catherine Klersy, Tiziano Moccetti, Stefan Toggweiler, Peiman Jamshidi, Fabien Praz, Stephan Windecker, André Vuilliomenet, Stephane Noble, Olivier Muller, Barbara Naegeli, Osmund Bertel, Raban Jeger, Peter Buser, Oliver Gaemperli, Francesco Maisano, Jürg Grünenfelder, Paul Erne, Giovanni Pedrazzini
Journal: Journal of the American College of Cardiology (2015)
Advanced pancreatic cancer: A single institution experience
Authors: S. De Dosso, M. Ghielmini, P. Saletti
Journal: Journal of Clinical Oncology (2008)

15647 Background: Despite recent progresses in the treatment of advanced pancreatic cancer (PC), the prognosis remains poor and many patients are unsuitable for any anticancer treatment. Methods: Records of 220 patients (pts) with locally advanced (97) or metastatic (123) PC admitted to the Oncology Institute of Southern Switzerland from 1993 to 2007 were reviewed: 119 males and 101 females, mean age of 64 years (range 32–89); ECOG performance status 0: 20%, 1: 50%, 2: 20%, 3: 10%. First-line chemotherapy (CxT) was administered to 170 pts (77%): 115 received single agent Gemcitabine (GEM), 27 5-Fluorouracil (5-FU), 15 GEM/5-FU or Capecitabine (CAP), 4 GEM/Oxaliplatin, 9 were enrolled in phase I studies.Sixty-five pts were treated with second-line regimens: 20 with single agent Fluoropyrimidine, 17 GEM/5-FU or CAP, 11 GEM monotherapy, 11 XELOX or FOLFOX, and 6 enrolled in phase I studies. Best supportive care (BSC) was proposed in 85 pts after failure of first-line CxT. Twelve pts were suitable for third-line regimens: 9 were enrolled in phase I studies and 3 underwent Oxaliplatin-based CxT. Forty-six pts were managed with BSC. Results: Median overall survival (OS) for females was 7.1 months (mo) and 6.2 mo for males (p=0.83). OS was not significantly worse in pts older than 65 years as compared to younger pts (4.1 vs 3.2 mo, p=0.079). In 162 evaluable pts treated with first-line CxT, overall response rate (ORR; partial response and stable disease) was 38% for single agent GEM, 48% for 5-FU, 55% for GEM combinations; symptoms improvement was observed in 30%. Median OS was 8.6 mo for pts treated with a first-line CxT and 2.08 mo for those managed with BSC (p<0.0001). ORR for second-line monotherapy was 15% and 30% for combination regimens; pts receiving second-line CxT had a median OS of 13.3 mo. Conclusions: In our experience, pts suitable for CxT experienced a survival advantage and the extent of CxT lines might amplify this benefit. Therefore, we encourage the inclusion in clinical trials after failure of first-line CxT. No significant financial relationships to disclose.
GW27-e0086 Incidence of pre-diabetes and type 2 diabetes among adults in Ahvaz, Iran: A 5 Year prospective study (2009-2014)
Authors: Majid Karandish, Seyed Mahmoud Latifi, Hajieh Shahbazian, Leila Hardanipasand
Journal: Journal of the American College of Cardiology (2016)
TCT-682 Impact of concomitant mitral regurgitation on mortality after transcatheter aortic valve replacement for severe aortic stenosis in high risk patients – results from a prospective single center registry
Authors: Stephan Haussig, Felix Woitek, Norman Mangner, Johannes Wilde, F. Schlotter, A. Lindner, Georg Stachel, David M. Holzhey, Friedrich-Wilhelm Mohr, Gerhard Schuler, Axel Linke
Journal: Journal of the American College of Cardiology (2015)